Dalantercept

Drug Profile

Dalantercept

Alternative Names: ACE-041; Activin Receptor-like Kinase 1 Inhibitor ACE-041; ALK1-Fc Fusion Protein ACE-041

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Gynecologic Oncology Group; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoglobulin fusion proteins
  • Mechanism of Action ACVRL1-protein-antagonists; Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I/II Hepatocellular carcinoma
  • Phase I Multiple myeloma; Solid tumours
  • Discontinued Endometrial cancer; Renal cell carcinoma

Most Recent Events

  • 23 Jun 2017 Discontinued - Phase-II for Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC)
  • 12 Jun 2017 Adverse events and efficacy data from the phase II DART trial in Renal cell carcinoma released by Acceleron Pharma
  • 01 Mar 2017 Discontinued - Phase-II for Endometrial cancer (Recurrent, Second-line therapy or greater) in USA (SC) (Acceleron Annual report, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top